by GlobeNewsWire | May 2, 2016 | Globe Newswire
SEATTLE, May 02, 2016 (GLOBE NEWSWIRE) — Researchers from the University of Pennsylvania today announced new animal study data evaluating the efficacy of an investigational adeno-associated virus (AAV) vector gene therapy treatment for X-linked retinitis...
by GlobeNewsWire | Apr 25, 2016 | Globe Newswire
ADVISORY, April 25, 2016 (GLOBE NEWSWIRE) — What: Voyager Therapeutics (Nasdaq:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), will visit the Nasdaq MarketSite in Times...
by GlobeNewsWire | Apr 22, 2016 | Globe Newswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 22, 2016 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of...
by GlobeNewsWire | Mar 24, 2016 | Globe Newswire
– Treated first patients in phase I/II clinical study of DTX101 for hemophilia B – – Expect to file an IND and initiate dosing for DTX301 for OTC deficiency in second half 2016 – – Selected candidate for GSDIa and expect to file an IND...
by GlobeNewsWire | Mar 17, 2016 | Globe Newswire
CAMBRIDGE, Mass., March 17, 2016 (GLOBE NEWSWIRE) — Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, liver-directed treatments for diverse rare diseases based on an adeno-associated virus (AAV) gene delivery technology,...